A PYMNTS Company

EU Closes Antitrust Case Against Edwards Lifesciences After Policy Withdrawal

By  |  February 16, 2026

European Union antitrust regulators have closed their investigation into U.S. medical device manufacturer Edwards Lifesciences after the company withdrew a disputed corporate policy, according to Reuters.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The European Commission, which serves as the bloc’s chief competition authority, had been examining whether Edwards’ internal rules unfairly restricted competition. The scrutiny followed a complaint lodged by Indian medical device maker Meril, a long-time rival of Edwards in global patent disputes involving heart valve technologies, per Reuters.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The Commission conducted a raid at one of Edwards’ facilities in the European Union in September 2023 amid concerns that the company may have misused its market position. At the center of the investigation was Edwards’ Global Unilateral Pro-Innovation (Anti-Copycatting) Policy, also known as UPIP. Meril argued that the policy could hinder competitors, according to Reuters.

    EU regulators confirmed that Edwards has since rescinded the policy. The Commission said the UPIP has been withdrawn, is no longer in effect, and has been removed from the company’s website.

    Related: FTC Lays Out Antitrust Concerns Over Edwards Lifesciences’ Planned JenaValve Acquisition

    “After thorough analysis and careful assessment of all evidence gathered and in light of Edwards Lifesciences’ withdrawal of the UPIP, the Commission has concluded that the investigated concerns have been addressed and further action is no longer considered a priority at EU level,” the Commission said in a statement.

    With the policy now scrapped, the Commission determined that additional enforcement steps were unnecessary, per Reuters. The closure of the case spares Edwards from potential penalties. Under EU competition rules, companies found to have violated antitrust laws can face fines of up to 10% of their global annual revenue.

    Source: Reuters